This MDRC renewal brings together talented new and experienced investigators, unique resources, and innovative techniques to develop medications for the treatment of Cocaine. heroin. and marijuana abuse. Existing medications for treating heroin addiction have serious flaws, and no effective agents have been developed for the other two drugs of abuse. The current MDRC has as its major theme the development of effective medications for subgroups of the addict population and the search for better methods to identify them. The renewal expands this focus to the development and/or utilization of models for more efficient and productive testing of promising medications, and consists of two Cores and five Projects, among which there is considerable interaction. The Administrative/Clinical Core, in addition to centralized recruiting, coordination, support and provision of basic psychosocial therapy, will carry out placebo-controlled pilot studies on promising new medications, and supports inpatient and outpatient research facilities for pilots and projects. The Statistical, Education, and Training Core provides statistical support, from design to analysis, and extensive education (with our Fellowship program) to medical students, residents, and fellows. Project 1 uses the smoked heroin self-administration model developed in the current MDRC to evaluate the buprenorphine/naloxone combination tablet, depot naltrexone, and two NMDA receptor antagonists. Project 2 combines innovative imaging of the Dl and D2 receptors with our model of cocaine self-administration to investigate whether the DI/D2 ratio is associated with cocaine craving and seeking, and thus could be a marker for rational medication development. Project 3 using the targeted subgroup model and innovative design features, builds on a promising pilot of venlafaxine, expanding it to a major double-blind clinical trial in depressed cocaine abusers. Project 4 aims to develop and implement a screening model for potential new agents for heroin detoxification. Using a three-arm screening model, an alphaadrenergic agonist, a calcium channel blocker, two NMDA antagonists and two partial opioid agonists will be compared to the alpha- adrenergic agonist clonidine. Project 5 proposes to develop a model for studying the effects of potential treatment medications with marijuana abusers, evaluating agents that may either ameliorate marijuana abstinence symptoms or reduce marijuana's acute effects. Overall, the Center has the potential to develop better medications and models for treating abuse of these three drugs, and, to meet this goal, has the unique ability to rapidly move back and forth between human laboratory and clinical studies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009236-10
Application #
6653783
Study Section
Special Emphasis Panel (ZDA1-RXL-E (22))
Program Officer
Montoya, Ivan
Project Start
1994-09-30
Project End
2004-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
10
Fiscal Year
2003
Total Cost
$2,089,914
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Brezing, Christina A; Choi, C Jean; Pavlicova, Martina et al. (2018) Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder. Am J Addict 27:101-107
Cooper, Ziva D; Bedi, Gillinder; Ramesh, Divya et al. (2018) Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 43:2046-2055
Chao, Thomas; Radoncic, Vanya; Hien, Denise et al. (2018) Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory. Drug Alcohol Depend 185:23-32
Metz, Verena E; Sullivan, Maria A; Jones, Jermaine D et al. (2017) Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. J Psychoactive Drugs 49:59-68
Metz, Verena E; Jones, Jermaine D; Manubay, Jeanne et al. (2017) Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. Neuropsychopharmacology 42:1825-1832
Vadhan, Nehal P; Corcoran, Cheryl M; Bedi, Gill et al. (2017) Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res 257:372-374
Bachtell, Ryan K; Jones, Jermaine D; Heinzerling, Keith G et al. (2017) Glial and neuroinflammatory targets for treating substance use disorders. Drug Alcohol Depend 180:156-170
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Cooper, Ziva D; Johnson, Kirk W; Pavlicova, Martina et al. (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 21:895-903
Herrmann, Evan S; Cooper, Ziva D; Bedi, Gillinder et al. (2016) Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl) 233:2469-78

Showing the most recent 10 out of 129 publications